Effects of omega 3 polyunsaturated fatty acids, antioxidants, and/or non‐steroidal inflammatory drugs in the brain of neonatal rats exposed to intermittent hypoxia
- 9 May 2021
- journal article
- research article
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 81 (5) , 448-460
Abstract
Preterm infants experience frequent arterial oxygen desaturations during oxygen therapy, or intermittent hypoxia (IH). Neonatal IH increases oxidative distress which contributes to neuroinflammation and brain injury. We tested the hypotheses that exposure to neonatal IH is detrimental to the immature brain, and that early supplementation with antioxidants and/or omega 3 polyunsaturated fatty acids (n‐3 PUFAs) combined with non‐steroidal anti‐inflammatory drugs (NSAIDs) is protective. Newborn rats were exposed to brief hypoxia (12% O2) during hyperoxia (50% O2) from the first day of life (P0) until P14 during which they received daily oral supplementation with antioxidants, namely coenzyme Q10 (CoQ10) or glutathione nanoparticles (nGSH), n‐3 PUFAs and/or topical ocular ketorolac. Placebo controls received daily oral olive oil and topical ocular saline. Room air (RA) littermates remained in 21% O2 from birth to P21 with all treatments identical. At P14 animals were allowed to recover in RA until P21 with no further treatment. Whole brains were harvested for histopathology and morphometric analyses, and assessed for biomarkers of oxidative stress and inflammation, as well as myelin injury. Neonatal IH resulted in higher brain/body weight ratios, an effect that was reversed with n‐3 PUFAs and n‐3 PUFAs+CoQ10 with or without ketorolac. Neonatal IH was also associated with hemorrhage, oxidative stress and elevations in inflammatory prostanoids. Supplementation with n‐3 PUFAs and nGSH with and without ketorolac were most beneficial for myelin growth and integrity when administered in RA. However, the benefit of n‐3 PUFAs was significantly curtailed in neonatal IH. Neonatal IH during a critical time of brain development causes inflammation and oxidative injury. Loss of therapeutic benefits of n‐3 PUFAs suggest its susceptibility to oxidation in neonatal IH and therefore indicate that co‐administration with antioxidants may be necessary to sustain its efficacy.Keywords
Funding Information
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (#U54HD071594)
This publication has 57 references indexed in Scilit:
- The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosisNature, 2019
- Comparative Effects of Coenzyme Q10 or n-3 Polyunsaturated Fatty Acid Supplementation on Retinal Angiogenesis in a Rat Model of Oxygen-Induced RetinopathyAntioxidants, 2018
- Co-Enzyme Q10 and n-3 Polyunsaturated Fatty Acid Supplementation Reverse Intermittent Hypoxia-Induced Growth Restriction and Improved Antioxidant Profiles in Neonatal RatsAntioxidants, 2017
- Pharmacologic synergism of ocular ketorolac and systemic caffeine citrate in rat oxygen-induced retinopathyPediatric Research, 2016
- A Water Soluble CoQ10 Formulation Improves Intracellular Distribution and Promotes Mitochondrial Respiration in Cultured CellsPLOS ONE, 2012
- Neonatal Apnea: What's New?Pediatric Pulmonology, 2008
- Three Distinct Mechanisms Generate Oxygen Free Radicals in Neurons and Contribute to Cell Death during Anoxia and ReoxygenationThe Journal of Neuroscience, 2007
- Relationships Between Organ Weight and Body/Brain Weight in the Rat: What Is the Best Analytical Endpoint?Toxicologic Pathology, 2004
- Roles of Cyclooxygenase (COX)-1 and COX-2 in Prostanoid Production by Human Endothelial Cells: Selective Up-Regulation of Prostacyclin Synthesis by COX-2The Journal of Immunology, 2001
- Characterization of inducible cyclooxygenase in rat brainJournal of Comparative Neurology, 1995